Pharmacological management of diabetic dyslipidemia

Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia

(2016) Ioanna Gouni-Berthold et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies

(2016) Helen M. Colhoun et al.   EUROPEAN HEART JOURNAL

2016 European Guidelines on cardiovascular disease prevention in clinical practice

(2016) Massimo F. Piepoli et al.   EUROPEAN HEART JOURNAL

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

(2016) Alberico L. Catapano et al.   EUROPEAN HEART JOURNAL

The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemia

(2016) Anastazia A. Kei et al.   Expert Opinion On Drug Safety

Hyaluronidase hypersensitivity: A rare complication of peribulbar block

(2016) AR Rajalakshmi et al.   INDIAN JOURNAL OF OPHTHALMOLOGY

Effects of ezetimibe/simvastatin combination on metabolic parameters

(2016) Theodosios D. Filippatos et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Effects of Statin Therapy on Plasma Proprotein Convertase Subtilisin/kexin Type 9 and Sortilin Levels in Statin-Naive Patients with Coronary Artery Disease

(2016) Tsuyoshi Nozue et al.   Journal of Atherosclerosis and Thrombosis

Statin therapy with or without ezetimibe and the progression to diabetes

(2016) Fotios Barkas et al.   Journal of Clinical Lipidology

2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

(2016) Donald M. Lloyd-Jones et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo

(2016) Peter P. Toth et al.   Lipids in Health and Disease

Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease

(2016) Tsuyoshi Nozue et al.   Lipids in Health and Disease

Dysfunctional high-density lipoproteins in coronary heart disease: implications for diagnostics and therapy

(2016) Wijtske Annema et al.   Translational Research

Pitavastatin and carbohydrate metabolism: what is the evidence?

(2016) T. D. Filippatos et al.   Expert Review of Clinical Pharmacology

Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data

(2016) Naveed Sattar et al.   Lancet Diabetes & Endocrinology

Statin–Ezetimibe Combination Therapy In Diabetic Individuals

(2015) Theodosios D. Filippatos et al.   ANGIOLOGY

A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate–statin combination therapy

(2015) Carlos Aguiar et al.   ATHEROSCLEROSIS SUPPLEMENTS

Effect of atorvastatin on glycaemia progression in patients with diabetes: an analysis from the Collaborative Atorvastatin in Diabetes Trial (CARDS)

(2015) Shona J. Livingstone et al.   DIABETOLOGIA

Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

(2015) Erik S. Stroes et al.   EUROPEAN HEART JOURNAL

Safety considerations with fenofibrate/simvastatin combination

(2015) Theodosios D Filippatos et al.   Expert Opinion On Drug Safety

Current lipid-modifying agents

(2015) Aris P Agouridis et al.   EXPERT OPINION ON PHARMACOTHERAPY

Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: A meta-analysis of randomized controlled trials

(2015) Chi-kin Ip et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial

(2015) G Kees Hovingh et al.   LANCET

Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study

(2015) John J P Kastelein et al.   LANCET

A randomized, double-blind, placebo-controlled study of the effect of ezetimibe on glucose metabolism in subjects with type 2 diabetes mellitus and hypercholesterolemia

(2015) Itori Saito et al.   Lipids in Health and Disease

Ezetimibe Stimulates Intestinal Glucagon-Like Peptide 1 Secretion Via the MEK/ERK Pathway Rather Than Dipeptidyl Peptidase 4 Inhibition

(2015) Eugene Chang et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease

(2015) Y. Zhang et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

PCSK9 Inhibition: Does Lipoprotein Size Matter?

(2015) Karim Si‐Tayeb et al.   Journal of the American Heart Association

Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis

(2014) Sebhat Erqou et al.   DIABETOLOGIA

The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial

(2014) Yumie Takeshita et al.   DIABETOLOGIA

The Effect of Rosuvastatin on Low-Density Lipoprotein Subfractions in Patients With Impaired Fasting Glucose

(2014) Christos V. Rizos et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

Ezetimibe combined with standard diet and exercise therapy improves insulin resistance and atherosclerotic markers in patients with metabolic syndrome

(2014) Kyoko Ohbu-Murayama et al.   Journal of Diabetes Investigation

Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia

(2013) Elisavet Moutzouri et al.   ATHEROSCLEROSIS

Lipids and lipid management in diabetes

(2013) Mamta Jaiswal et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Dyslipidemia, but not hyperglycemia and insulin resistance, is associated with marked alterations in the HDL lipidome in type 2 diabetic subjects in the DIWA cohort: Impact on small HDL particles

(2013) Marcus Ståhlman et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

Effects of High-Density Lipoprotein Elevation With Cholesteryl Ester Transfer Protein Inhibition on Insulin Secretion

(2013) Andrew L. Siebel et al.   CIRCULATION RESEARCH

Fenofibrate and the kidney: an overview

(2013) Michael S. Kostapanos et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Small High-Density Lipoprotein (HDL) Subclasses are Increased with Decreased Activity of HDL-Associated Phospholipase A2 in Subjects with Prediabetes

(2013) Theodosios D. Filippatos et al.   LIPIDS

PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics

(2013) Rose Q. Do et al.   Current Cardiology Reports

Meta-Analysis of Safety of the Coadministration of Statin With Fenofibrate in Patients With Combined Hyperlipidemia

(2012) Jinrui Guo et al.   AMERICAN JOURNAL OF CARDIOLOGY

Emphasizing Statin Safety in the Hospitalized Patient: A Review

(2012) Alicia Leung et al.   AMERICAN JOURNAL OF MEDICINE

Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: A retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development program

(2012) Evan A. Stein et al.   ATHEROSCLEROSIS

Effect of simvastatin or its combination with ezetimibe on Toll-like receptor expression and lipopolysaccharide – Induced cytokine production in monocytes of hypercholesterolemic patients

(2012) Elisavet Moutzouri et al.   ATHEROSCLEROSIS

Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials

(2012) Doralisa Morrone et al.   ATHEROSCLEROSIS

A Review of Time Courses and Predictors of Lipid Changes with Fenofibric Acid-Statin Combination

(2012) Theodosios D. Filippatos   CARDIOVASCULAR DRUGS AND THERAPY

Simvastatin interactions with other drugs

(2012) Matilda Florentin et al.   Expert Opinion On Drug Safety

Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome

(2012) A. P. Agouridis et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Use of Administrative Data to Estimate the Incidence of Statin-Related Rhabdomyolysis

(2012) Susan R. Heckbert   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effect of Atorvastatin Monotherapy and Low-Dose Atorvastatin/Ezetimibe Combination on Fasting and Postprandial Triglycerides in Combined Hyperlipidemia

(2012) Michael S. Kostapanos et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

Effects of Statin Monotherapy Versus Statin Plus Ezetimibe Combination on Serum Uric Acid Levels

(2012) Elisavet Moutzouri et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial

(2012) Paul M Ridker et al.   LANCET

The biology and therapeutic targeting of the proprotein convertases

(2012) Nabil G. Seidah et al.   NATURE REVIEWS DRUG DISCOVERY

Clinical aspects of PCSK9

(2011) Bertrand Cariou et al.   ATHEROSCLEROSIS

Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: A meta-analysis

(2011) Meng Lee et al.   ATHEROSCLEROSIS

Effect of Torcetrapib on Glucose, Insulin, and Hemoglobin A 1c in Subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial

(2011) Philip J. Barter et al.   CIRCULATION

Effects of hypolipidemic and hypoglycemic agents on atherogenic small, dense LDL in Type 2 diabetes

(2011) Manfredi Rizzo et al.   Clinical Lipidology

Fixed-Dose Combination Fenofibrate/Pravastatin 160/40 mg Versus Simvastatin 20 mg Monotherapy in Adults With Type 2 Diabetes and Mixed Hyperlipidemia Uncontrolled With Simvastatin 20 mg: A Double-Blind, Randomized Comparative Study

(2011) Michel Farnier et al.   CLINICAL THERAPEUTICS

Role of Phospholipid Transfer Protein in High-Density Lipoprotein– Mediated Reverse Cholesterol Transport

(2011) Amirfarbod Yazdanyar et al.   Current Atherosclerosis Reports

Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges

(2011) Uchechukwu K. Sampson et al.   Current Atherosclerosis Reports

The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia

(2011) Matilda Florentin et al.   CURRENT MEDICAL RESEARCH AND OPINION

“European Panel on Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses

(2011) Dimitri P. Mikhailidis et al.   Current Vascular Pharmacology

Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study

(2011) L. A. Leiter et al.   DIABETIC MEDICINE

The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia

(2011) Aris P Agouridis et al.   EXPERT OPINION ON PHARMACOTHERAPY

Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia

(2011) Theodosios D Filippatos et al.   EXPERT OPINION ON PHARMACOTHERAPY

Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient

(2011) G. F. Watts et al.   HEART

Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy

(2011) David Preiss   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The differential effect of statins on oxidative stress and endothelial function: Atorvastatin versus pravastatin

(2011) Jonathan R. Murrow et al.   Journal of Clinical Lipidology

Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib

(2011) Ronald M. Krauss et al.   JOURNAL OF LIPID RESEARCH

High Doses of Rosuvastatin are Superior to Low Doses of Rosuvastatin Plus Fenofibrate or n-3 Fatty Acids in Mixed Dyslipidemia

(2011) A. P. Agouridis et al.   LIPIDS

Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Ezetimibe improves glucose metabolism by ameliorating hepatic function in Japanese patients with type 2 diabetes

(2011) Shinji Ichimori et al.   Journal of Diabetes Investigation

Efficacy and Safety of Fenofibric Acid Co-Administered with Low- or Moderate-Dose Statin in Patients with Mixed Dyslipidemia and Type 2 Diabetes Mellitus

(2010) Peter H. Jones et al.   American Journal of Cardiovascular Drugs

Efficacy and Safety of Rosuvastatin and Fenofibric Acid Combination Therapy versus Simvastatin Monotherapy in Patients with Hypercholesterolemia and Hypertriglyceridemia

(2010) Eli M. Roth et al.   American Journal of Cardiovascular Drugs

Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes

(2010) Manfredi Rizzo et al.   ANGIOLOGY

Efficacy and Safety of Rosuvastatin 5 mg in Combination with Fenofibric Acid 135 mg in Patients with Mixed Dyslipidemia – A Phase 3 Study

(2010) Eli M. Roth et al.   CARDIOVASCULAR DRUGS AND THERAPY

Combination of Fenofibrate with Non-Statin Drug Regimens

(2010) A. P. Agouridis et al.   CURRENT PHARMACEUTICAL DESIGN

Effect of Non-Statin Lipid Lowering and Anti-Obesity Drugs on LDL Subfractions in Patients with Mixed Dyslipidaemia

(2010) Matilda Florentin et al.   Current Vascular Pharmacology

Do Statins Beneficially or Adversely Affect Glucose Homeostasis?

(2010) Michael S. Kostapanos et al.   Current Vascular Pharmacology

Pleiotropic Effects of Atorvastatin and Fenofibrate in Metabolic Syndrome and Different Types of Pre-Diabetes

(2010) R. Krysiak et al.   DIABETES CARE

Pleiotropic effects of ezetimibe: Do they really exist?

(2010) Michalis Kalogirou et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Should we measure routinely oxidised and atherogenic dense low-density lipoproteins in subjects with type 2 diabetes?

(2010) M. Rizzo et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

(2010) The Emerging Risk Factors Collaboration   LANCET

Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies

(2010)   LANCET

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis

(2010) Min Jun et al.   LANCET

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

(2010) Naveed Sattar et al.   LANCET

The Effects of Ezetimibe and/or Orlistat on Triglyceride-Rich Lipoprotein Metabolism in Obese Hypercholesterolemic Patients

(2010) E. S. Nakou et al.   LIPIDS

Combination Lipid Therapy in Type 2 Diabetes

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease

(2010) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170 255 patients from 76 randomized trials

(2010) E. J. Mills et al.   QJM-AN INTERNATIONAL JOURNAL OF MEDICINE

Meta-analysis of Comparative Efficacy of Increasing Dose of Atorvastatin Versus Rosuvastatin Versus Simvastatin on Lowering Levels of Atherogenic Lipids (from VOYAGER)

(2009) Stephen J. Nicholls et al.   AMERICAN JOURNAL OF CARDIOLOGY

Plasma triglyceride levels and body mass index values are the most important determinants of preβ-1 HDL concentrations in patients with various types of primary dyslipidemia

(2009) Vasilis Tsimihodimos et al.   ATHEROSCLEROSIS

The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: An updated meta-analysis

(2009) Philippa J. Delahoy et al.   CLINICAL THERAPEUTICS

Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients

(2009) Giuseppe Derosa et al.   CURRENT MEDICAL RESEARCH AND OPINION

Pleiotropic Effects of Statins - Clinical Evidence

(2009) Vasilios Athyros et al.   CURRENT PHARMACEUTICAL DESIGN

Lipid-Lowering Drugs Acting at the Level of the Gastrointestinal Tract

(2009) T. Filippatos et al.   CURRENT PHARMACEUTICAL DESIGN

Effects of atorvastatin 10 mg and fenofibrate 200 mg on the low-density lipoprotein profile in dyslipidemic patients: A 12-week, multicenter, randomized, open-label, parallel-group study

(2009) Jean-Claude Ansquer et al.   CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL

Effects of Long-Term Fenofibrate Treatment on Markers of Renal Function in Type 2 Diabetes: The FIELD Helsinki substudy

(2009) C. Forsblom et al.   DIABETES CARE

Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles

(2009) K. Winkler et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Pleiotropic Effects of Atorvastatin on Monocytes in Atherosclerotic Patients

(2009) Zhi-hao Wang et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention

(2009) Pierre Amarenco et al.   LANCET NEUROLOGY

Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: A phase 3, randomized, controlled study

(2008) Syed M. Mohiuddin et al.   AMERICAN HEART JOURNAL

Comparison of Effects of Simvastatin Alone Versus Fenofibrate Alone Versus Simvastatin Plus Fenofibrate on Lipoprotein Subparticle Profiles in Diabetic Patients With Mixed Dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen Study)

(2008) Heidi T. May et al.   AMERICAN JOURNAL OF CARDIOLOGY

Statins and Heart Failure

(2008) Theodosios D. Filippatos et al.   ANGIOLOGY

Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: A phase 3 study

(2008) Peter H. Jones et al.   ATHEROSCLEROSIS

The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials

(2008) K. Josan et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia

(2008) E. S. Nakou et al.   CURRENT MEDICAL RESEARCH AND OPINION

Multiple actions of high-density lipoprotein

(2008) Matilda Florentin et al.   CURRENT OPINION IN CARDIOLOGY

Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

(2008) R. Scott et al.   DIABETES CARE

Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia

(2008) Michael S. Kostapanos et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Treatment of hyperlipidaemia with fenofibrate and related fibrates

(2008) Theodosios Filippatos et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study

(2008) CS Derdemezis et al.   EXPERT OPINION ON PHARMACOTHERAPY

Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study

(2008) M Florentin et al.   EXPERT OPINION ON PHARMACOTHERAPY

The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia

(2008) ES Nakou et al.   EXPERT OPINION ON PHARMACOTHERAPY

Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes

(2008) Kaspar Berneis et al.   EXPERT OPINION ON PHARMACOTHERAPY

Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia

(2008) Harold E. Bays et al.   Journal of Clinical Lipidology

Primary Prevention of Cardiovascular Mortality and Events With Statin Treatments

(2008) Edward J. Mills et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Statins and diabetes – Authors' reply

(2008) Patricia M Kearney et al.   LANCET

Alterations in the High Density Lipoprotein Phenotype and HDL-Associated Enzymes in Subjects with Metabolic Syndrome

(2008) K. G. Lagos et al.   LIPIDS

The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome

(2007) T. D. Filippatos et al.   DIABETES OBESITY & METABOLISM

Hypertriglyceridaemic waist phenotype criteria and prevalent metabolic triad in women

(2007) Irene F. Gazi et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS